Abstract
An effective vaccine delivery system has been developed for vaccination against a blood-stage malaria infection in mice. Subcutaneous vaccination with a semi-purified asexual blood-stage malaria antigen combined with an adjuvant formulation containing squalane, Tween 80 and pluronic L121 (AF) protected mice infected with a lethal P. yoelii infection against death and greatly reduced the severity and duration of parasitaemia. The adjuvant and the route of immunization are both clinically acceptable, thereby making this an attractive delivery system for a human malaria vaccine. Protective immunity appeared to be associated with an enhancement of both Th1 and Th2 subset cytokines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
